eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
2/2018
vol. 13
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł oryginalny

Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria

Aleksander Szadkowski, Magdalena Zemlak, Jacek Muszyński

Data publikacji online: 2018/05/16
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Introduction
The treatment of Helicobacter pylori (HP) tends to be empirical despite a high number of failures (over 20%). The efficacy of eradication therapies is declining, reaching in some countries 60%, which correlates inversely with the growing drug resistance of the bacteria.

Aim
Given the frequent inefficacy of the hitherto proposed treatment schemes for HP infection, an attempt was made to assess the efficacy of a therapy based on the antibiotic resistance of the cultured bacteria, and to analyse factors with possible contribution to the inefficacy of HP eradication treatment.

Material and methods
The study covered patients from one region of Central Poland in the years 2005–2015. The total material for bacteriological assessment was collected from 154 patients who had previously been subject to HP eradication treatment at least two times, including 80 women and 74 men, reporting subsequently to the Clinic.

Results
The efficacy of the antibiogram-based treatment was merely 65.62%. A low, but slightly higher than expected, resistance to amoxicillin (3.48%) and tetracycline (2.27%), as well as to clarithromycin (27.27%) and metronidazole (70.69%), was established.

Conclusions
In Polish patients resistance to clarithromycin and metronidazole of HP is high and becoming increasingly resistant; however, we found low bacterial resistance to tetracycline.

referencje:
Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointest Liver Dis 2011; 20: 299-304.
Łaszewicz W. The results of research on Helicobacter pylori infection. Trans-Humana. Wydawnictwo Uniwersyteckie, Białystok 2004.
Matysiak-Budnik T, Knapik Z, Mégraud F, et al. Helicobacter pylori infection in Eastern Europe: seroprevalence in the Polish population of Lower Silesia. Am J Gastroenterol 1996; 91: 2513-5.
Szadkowski A, Chojnacki J, Klupińska G, et al. Clinical analysis of unsuccessful Helicobacter pylori eradication. Pol Merkuriusz Lek 2005; 17: 139-41.
Gisbert JP, Martín de Argila C, Redondo C, et al. New one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic. Med Clin (Barc) 1998; 110: 1-5.
Muszyński J, Czyżyk A, Biernacka D, et al. Combined treatment of Helicobacter pylori infection-7-day or 14-day treatment? Pol Tyg Lek 1992; 47: 641-5.
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not change over the last decade, but is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
Gisbert JP, Pajares JM. Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
Holubiuk L, Imiela J. Diet and Helicobacter pylori infection. Gastroenetrology Rev 2016; 11: 150-4.
Glupczynski Y, Mégraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-64.
Dzierżanowska-Fangrat K, Rozynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicenter study. Int J Antimicorb Agents 2005; 26: 230-4.
Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther Therapeutics 2003; 17: 1545-51.
Bartnik W, Celińska-Cedro D, Dzieniszewski J, et al. Guidelines from the Polish Society of Gastroenterology for the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Prakt 2014; 2: 33-41.
Dzieniszewski J, Jarosz M et al. Guidelines from the Polish Society of Gastroenterology for the diagnosis and treatment of Helicobacter pylori infection – consensus 2008. Gastroenterol Pol 2008; 15: 323-31.
Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
Sugano K, Tack J, Kuipers EJ, el al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-67.
Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008; 8: 593-7.
Wenzhen Y, Yumin L, Quanin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103-9.
Sugimoto M, Furata T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 2014; 20: 6400-11.
Avidan B, Mezler E, Keller N, et al. The effect of culture result for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001; 3: 163-5.
Selgrad M, Tammer I, Langner C, et al. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014; 20: 16245-51.
Paradowska A, Sieja A, Braksator M. Helicobacter pylori infection and oral cavity. Gastroenterol Pol 2010; 17: 423-6.
Marais A, Monteiro L, Lamouliatte H, et al. Cag negative status of Helicobacter pylori is a risk factor for failure of PPI-based triple therapies in non-ulcer dyspepsia. Gastroenterology 1998; 114: A214.
Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-24.
Al-Medhagi AS. Eradication of Helicobacter pylori in outpatients by using triple drug therapy. Gastroenterol Pol 2004; 11: 11-4.
Zullo A, Hassan C, Lorenzetti R, et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with the capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24: 395-403.
Sanchez-Delgado J, Garcia-Iglesias P, Castro-Fernandez M, et al. High-dose, ten-days esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012; 36: 190-6.
Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori Infection in adults. Gastroenterology 2016; 151: 51-69.
Research C for DE and. Information by Drug Class – FDA approves safety labeling changes for fluoroquinolones https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm500325.htm (accessed April 9, 2017).
Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008; 8: 593-7.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe